ECM
CDTX

Element Capital Management’s Cidara Therapeutics CDTX Stock Holding History

Element Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,117
Closed -$318K – 71
2017
Q2 		$318K Buy
+2,117
New +$293K 0.06% 65

Other funds holding CDTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Element Capital Management's CDTX Position: Q3 2017 in Review

Element Capital Management sold out of Cidara Therapeutics (CDTX) in Q3 2017, closing a stake of 2,117 shares — an estimated $318K sold.

Element Capital Management first reported a position in CDTX in Q2 2017 and held it in 1 quarter. The position peaked at $318K in Q2 2017. 42 funds tracked by Wall St. Rank hold CDTX as of Q3 2017.

  • Element Capital Management reported no remaining Cidara Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Element Capital Management sold 2,117 Cidara Therapeutics shares in Q3 2017, an estimated $318K.
  • Element Capital Management first reported a position in Cidara Therapeutics in Q2 2017 and held it in 1 quarter.
  • Element Capital Management's Cidara Therapeutics position peaked at $318K in Q2 2017.
  • 42 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2017.

Based on Element Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.